Sanjay Navin Mediwala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sanjay Navin Mediwala has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Marco Marcelli
Michael E. DeBakey VA Medical Center, Houston, TX, USA
5 shared publications Adam T. Szafran
Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas
3 shared publications- Michael A. Mancini
Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, United States
3 shared publications - Dennis Tan Villareal
Division of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine, Houston, TX 77030, USA; Center for Translational Research on Inflammatory Diseases, Michael E.DeBakey (VA) Medical Center, Houston, TX 77030, USA
2 shared publications Huiying Sun
Department of Medicine, Baylor College of Medicine, Houston, Texas
2 shared publications- Sean M. Hartig
Division of Diabetes, Endocrinology, and Metabolism, Baylor College of Medicine, Houston, TX
2 shared publications
Latest Publications
- 3 November 2023
- Published by Taylor & Francis
- p. 565-571
Obesity, Osteoarthritis, and Bone Disorders
This chapter describes the interaction of obesity with disorders of bone fragility and osteoarthritis. Obesity is linked to these conditions through its effects on biomechanics and systemic inflammation. Obesity has a complex interaction with fracture risk. Though high body mass index (BMI) appears to be associated with a minor decrease in the risk of fracture, obesity-associated frailty and increased visceral adiposity increase the risk of fracture. Clinical management includes screening appropriate populations and intervention with lifestyle changes, vitamin D and mineral supplementation, and osteoporosis pharmacotherapy. The effects of voluntary weight loss on fracture risk are not definitively known. Osteoarthritis (OA) is increased in obesity in both weight-bearing and non-weight-bearing joints. Weight loss appears to be an effective intervention for reducing pain with knee and hip OA in patients with obesity and requires either a potent weight reduction intervention such as bariatric surgery, or the combination of diet and exercise, with an achieved weight loss of at least 6%. Obesity in patients undergoing total joint arthroplasty (TJA) is associated with greater short- and long-term surgical complications, and weight-loss interventions should be considered in select patients prior to TJA.
- 3 November 2023
- Published by Taylor & Francis
- p. 565-571
Obesity, Osteoarthritis, and Bone Disorders
This chapter describes the interaction of obesity with disorders of bone fragility and osteoarthritis. Obesity is linked to these conditions through its effects on biomechanics and systemic inflammation. Obesity has a complex interaction with fracture risk. Though high body mass index (BMI) appears to be associated with a minor decrease in the risk of fracture, obesity-associated frailty and increased visceral adiposity increase the risk of fracture. Clinical management includes screening appropriate populations and intervention with lifestyle changes, vitamin D and mineral supplementation, and osteoporosis pharmacotherapy. The effects of voluntary weight loss on fracture risk are not definitively known. Osteoarthritis (OA) is increased in obesity in both weight-bearing and non-weight-bearing joints. Weight loss appears to be an effective intervention for reducing pain with knee and hip OA in patients with obesity and requires either a potent weight reduction intervention such as bariatric surgery, or the combination of diet and exercise, with an achieved weight loss of at least 6%. Obesity in patients undergoing total joint arthroplasty (TJA) is associated with greater short- and long-term surgical complications, and weight-loss interventions should be considered in select patients prior to TJA.
- 26 August 2022
- Published by Springer Nature
- p. 373-383
Benefits and Risks of Testosterone Replacement in the Older Man with Hypogonadism
- 26 August 2022
- Published by Springer Nature
- p. 373-383
Benefits and Risks of Testosterone Replacement in the Older Man with Hypogonadism
- Open Access
- 1 March 2021
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 21, 100723
Testosterone therapy and bone quality in men with diabetes and hypogonadism: Study design and protocol
- 1 March 2021
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 21, 100723
Open AccessTestosterone therapy and bone quality in men with diabetes and hypogonadism: Study design and protocol
- 20 July 2012
- Published by Wiley in The Prostate
- Vol. 73 (3) , 267-277
The activity of the androgen receptor variant AR‐V7 is regulated by FOXO1 in a PTEN‐PI3K‐AKT‐dependent way
BACKGROUND: The androgen receptor (AR) AR‐V7 splice isoform is a constitutively active outlaw transcription factor. Transition of prostate cancer (PC) to the castration‐resistant phenotype correlates with AR‐V7 accumulation, suggesting that PC progression in patients refractory to conventional therapy is due to the activity of this AR isoform. The mechanism of AR‐V7 constitutive activation is not known.METHODS: We analyzed potential signaling pathways associated with AR‐V7 constitutive activation in PTEN (−) PC‐3 and LNCaP cells. We used transient and stable transfection, reporter gene assay, RNAi technology together with a number of kinase inhibitors to determine if AR‐V7 activation is linked to a kinase‐dependent signaling pathway.RESULTS: In these cell lines, AR‐V7 transcriptional activity was inhibited by LY294002, Wortmanin, and AKT inhibitor II. Analysis of the contributing mechanisms demonstrated the involvement of the Phosphatidylinositol 3‐kinase (PI3K)‐AKT‐FOXO1 signaling pathway, and a significant reduction of AR‐V7 constitutive activity under conditions of PTEN reactivation.CONCLUSIONS: Our study identifies a pathway regulating AR‐V7 constitutive activity and potential therapeutic targets for the treatment of castration‐resistant PC. Prostate 73: 267–277, 2013.
- 20 July 2012
- Published by Wiley in The Prostate
- Vol. 73 (3) , 267-277
The activity of the androgen receptor variant AR‐V7 is regulated by FOXO1 in a PTEN‐PI3K‐AKT‐dependent way
BACKGROUND: The androgen receptor (AR) AR‐V7 splice isoform is a constitutively active outlaw transcription factor. Transition of prostate cancer (PC) to the castration‐resistant phenotype correlates with AR‐V7 accumulation, suggesting that PC progression in patients refractory to conventional therapy is due to the activity of this AR isoform. The mechanism of AR‐V7 constitutive activation is not known.METHODS: We analyzed potential signaling pathways associated with AR‐V7 constitutive activation in PTEN (−) PC‐3 and LNCaP cells. We used transient and stable transfection, reporter gene assay, RNAi technology together with a number of kinase inhibitors to determine if AR‐V7 activation is linked to a kinase‐dependent signaling pathway.RESULTS: In these cell lines, AR‐V7 transcriptional activity was inhibited by LY294002, Wortmanin, and AKT inhibitor II. Analysis of the contributing mechanisms demonstrated the involvement of the Phosphatidylinositol 3‐kinase (PI3K)‐AKT‐FOXO1 signaling pathway, and a significant reduction of AR‐V7 constitutive activity under conditions of PTEN reactivation.CONCLUSIONS: Our study identifies a pathway regulating AR‐V7 constitutive activity and potential therapeutic targets for the treatment of castration‐resistant PC. Prostate 73: 267–277, 2013.
- 14 December 2011
- Published by Springer Nature
- p. 227-252
Quantitative Visualization of Sex Steroid Receptor Functions: AR and ERα
- 14 December 2011
- Published by Springer Nature
- p. 227-252
Quantitative Visualization of Sex Steroid Receptor Functions: AR and ERα
- Open Access
- 6 June 2011
- Published by Springer Nature
- Vol. 707, 63-65
Androgen Receptor Mutations Associated with Androgen Insensitivity Syndrome: A High Content Analysis Approach Leading to Personalized Medicine
- 6 June 2011
- Published by Springer Nature
- Vol. 707, 63-65
Open AccessAndrogen Receptor Mutations Associated with Androgen Insensitivity Syndrome: A High Content Analysis Approach Leading to Personalized Medicine
- 1 June 2010
- Published by The Endocrine Society
- p. P1-350
Insulin Potentiates Androgen Receptor Activity
Article published by the Endocrine Society Article published by the Endocrine Society
- 1 June 2010
- Published by The Endocrine Society
- p. P1-350
Insulin Potentiates Androgen Receptor Activity
Article published by the Endocrine Society Article published by the Endocrine Society
- Open Access
- 9 December 2009
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 4 (12) , e8179
Androgen Receptor Mutations Associated with Androgen Insensitivity Syndrome: A High Content Analysis Approach Leading to Personalized Medicine
Androgen insensitivity syndrome (AIS) is a rare disease associated with inactivating mutations of AR that disrupt male sexual differentiation, and cause a spectrum of phenotypic abnormalities having as a common denominator loss of reproductive viability. No established treatment exists for these conditions, however there are sporadic reports of patients (or recapitulated mutations in cell lines) that respond to administration of supraphysiologic doses (or pulses) of testosterone or synthetic ligands. Here, we utilize a novel high content analysis (HCA) approach to study AR function at the single cell level in genital skin fibroblasts (GSF). We discuss in detail findings in GSF from three historical patients with AIS, which include identification of novel mechanisms of AR malfunction, and the potential ability to utilize HCA for personalized treatment of patients affected by this condition.
- 9 December 2009
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 4 (12) , e8179
Open AccessAndrogen Receptor Mutations Associated with Androgen Insensitivity Syndrome: A High Content Analysis Approach Leading to Personalized Medicine
Androgen insensitivity syndrome (AIS) is a rare disease associated with inactivating mutations of AR that disrupt male sexual differentiation, and cause a spectrum of phenotypic abnormalities having as a common denominator loss of reproductive viability. No established treatment exists for these conditions, however there are sporadic reports of patients (or recapitulated mutations in cell lines) that respond to administration of supraphysiologic doses (or pulses) of testosterone or synthetic ligands. Here, we utilize a novel high content analysis (HCA) approach to study AR function at the single cell level in genital skin fibroblasts (GSF). We discuss in detail findings in GSF from three historical patients with AIS, which include identification of novel mechanisms of AR malfunction, and the potential ability to utilize HCA for personalized treatment of patients affected by this condition.